Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA.
Clin Genet. 2012 Oct;82(4):388-94. doi: 10.1111/j.1399-0004.2012.01908.x. Epub 2012 Jul 3.
It is anticipated that as the range of drugs for which pharmacogenetic testing becomes available expands, primary care physicians (PCPs) will become major users of these tests. To assess their training, familiarity, and attitudes toward pharmacogenetic testing in order to identify barriers to uptake that may be addressed at this early stage of test use, we conducted a national survey of a sample of PCPs. Respondents were mostly white (79%), based primarily in community-based primary care (81%) and almost evenly divided between family medicine and internal medicine. The majority of respondents had heard of PGx testing and anticipated that these tests are or would soon become a valuable tool to inform drug response. However, only a minority of respondents (13%) indicated they felt comfortable ordering PGx tests and almost a quarter reported not having any education about pharmacogenetics. Our results indicate that primary care practitioners envision a major role for themselves in the delivery of PGx testing but recognize their lack of adequate knowledge and experience about these tests. Development of effective tools for guiding PCPs in the use of PGx tests should be a high priority.
预计随着可供基因检测的药物范围扩大，初级保健医生（PCP）将成为这些检测的主要使用者。为了评估他们的培训、熟悉程度和对基因检测的态度，以便在测试使用的早期阶段发现可能存在的障碍，并加以解决，我们对初级保健医生进行了一项全国性抽样调查。受访者主要是白人（79%），主要来自社区基础的初级保健（81%），并在家庭医学和内科之间几乎平分秋色。大多数受访者听说过 PGx 测试，并预计这些测试是或很快将成为一种有价值的工具，可以了解药物反应。然而，只有少数受访者（13%）表示他们觉得自己能够订购 PGx 测试，近四分之一的人表示他们没有接受过任何关于药物遗传学的教育。我们的结果表明，初级保健医生期望自己在提供 PGx 测试方面发挥重要作用，但也认识到他们缺乏有关这些测试的足够知识和经验。开发有效的工具来指导初级保健医生使用 PGx 测试应该是当务之急。
